Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
The major depressive disorder market is experiencing a significant transformation as rapid-acting therapies with novel mechanisms of action complement conventional SSRIs and SNRIs. Recent treatment approvals have broadened therapeutic choices for patients with TRD and those who do not achieve adequate benefit from standard antidepressants. Meanwhile, pipeline candidates such as Seltorexant (Johnson & Johnson), Azetukalner (Xenon Pharmaceuticals), Itruvone (VistaGen), and others are advancing through clinical development to deliver improved efficacy, faster symptom relief, and better tolerability for individuals with persistent depressive symptoms.
LAS VEGAS, Aug. 10, 2026 /PRNewswire/ -- Recently published Major Depressive Disorder Market Insights report includes a comprehensive understanding of current treatment practices, major depressive disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Major Depressive Disorder Market Summary
Discover what medications are successful for treating major depressive disorder @ https://www.delveinsight.com/report-store/major-depressive-disorder-market
Key Factors Driving the Growth of the Major Depressive Disorder Market
Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that among emerging therapies, seltorexant is expected to demonstrate moderate-to-strong uptake potential, particularly in MDD patients with insomnia and sleep-related symptoms, reflecting growing interest in orexin-targeted therapies.
Major Depressive Disorder Market Analysis
Major Depressive Disorder Competitive Landscape
Some of the major depressive disorder medications under development include Seltorexant (Johnson & Johnson), Azetukalner (Xenon Pharmaceuticals), Itruvone (PH10) (VistaGen), HLP003 (Helus Pharma), Osavampator (Neurocrine Biosciences), Brenipatide (Eli Lilly), Bretisilocin and Icalcaprant (ABBV-1354) (AbbVie), Elunetirom (ABX-002) (Autobahn Therapeutics), DT120 (Definium Therapeutics), Zelquistinel (Syndeio Biosciences), Forvisirvat (SP-624) (Arrivo), ALTO-300 (Alto Neuroscience), GlyphAllo (SPT-300) (Seaport Therapeutics), and others.
Johnson & Johnson's Seltorexant is an investigational, first-in-class selective orexin-2 (OX2) receptor antagonist being evaluated as an adjunctive therapy for patients with major depressive disorder (MDD) who experience insomnia symptoms. It is the only investigational candidate in MDD designed to modulate excessive orexin-2 receptor activity, aiming to address the biological mechanisms underlying both depressive symptoms and sleep disturbances.
Xenon Pharmaceuticals' Azetukalner is an innovative and highly potent KV7 potassium channel opener currently undergoing Phase III clinical development for epilepsy, MDD, and bipolar depression (BPD). As the most advanced potassium channel modulator in late-stage development, it is supported by long-term efficacy and safety data from epilepsy studies, along with proof-of-concept evidence in MDD. It is also the only KV7 potassium channel opener being investigated across multiple therapeutic indications.
Alto Neuroscience's ALTO-300 is a small-molecule therapy with melatonergic agonist and serotonergic antagonist properties that enhances dopamine and norepinephrine activity. The drug is being developed in the United States as an adjunctive treatment for MDD in patients identified through EEG biomarker profiling. Although ALTO-300 has already demonstrated antidepressant efficacy and is approved for treating MDD in Europe and Australia, it has not yet received regulatory approval in the United States.
In a Phase IIa clinical study, ALTO-300 showed encouraging efficacy as an add-on therapy for patients with MDD who had an inadequate response to standard antidepressants. Individuals selected using a machine learning-derived EEG biomarker experienced significantly greater improvements in Montgomery–Åsberg Depression Rating Scale (MADRS) scores compared with baseline. Building on these positive findings, the developer initiated a randomized, double-blind, placebo-controlled Phase IIb trial to further evaluate ALTO-300 in EEG biomarker-defined patients with MDD.
Seaport Therapeutics' GlyphAllo is an investigational oral prodrug of allopregnanolone developed using the proprietary Glyph technology platform. Allopregnanolone is a naturally occurring neuroactive steroid that has demonstrated rapid antidepressant, anxiolytic, and sleep-enhancing effects in previous clinical studies. However, its clinical utility has been limited by poor oral bioavailability.
Glyph technology is intended to improve the oral absorption of allopregnanolone, enabling GlyphAllo to overcome these pharmacokinetic limitations. The candidate also has the potential to reduce treatment-related adverse effects commonly associated with existing antidepressants, including sexual dysfunction, weight gain, and sleep disturbances.
The anticipated launch of these emerging therapies are poised to transform the major depressive disorder market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the major depressive disorder market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the best brands for major depressive disorder treatment @ Major Depressive Disorder Medication
Recent Developments in the Major Depressive Disorder Market
Major Depressive Disorder Epidemiology Segmentation
The major depressive disorder epidemiology section provides insights into the historical and current major depressive disorder patient pool and forecasted trends for the leading markets. In 2025, the US accounted for the highest diagnosed prevalent cases of MDD in the 7MM, with ~22 million cases.
The major depressive disorder treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Major Depressive Disorder Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Major Depressive Disorder Market Size in 2025
USD 7.8 Billion
Key Major Depressive Disorder Companies
Johnson & Johnson, Xenon Pharmaceuticals, VistaGen, Helus Pharma, Neurocrine Biosciences, Eli Lilly, AbbVie, Autobahn Therapeutics, Definium Therapeutics, Syndeio Biosciences, Arrivo, Alto Neuroscience, Seaport Therapeutics, Axsome Therapeutics, and others
Key Major Depressive Disorder Therapies
Seltorexant, Azetukalner, Itruvone (PH10), HLP003, Osavampator, Brenipatide, Bretisilocin, Icalcaprant (ABBV-1354), Elunetirom (ABX-002), DT120, Zelquistinel, Forvisirvat (SP-624), ALTO-300, GlyphAllo (SPT-300), CAPLYTA, SPRAVATO, AUVELITY, and others
Scope of the Major Depressive Disorder Market Report
Download the report to understand the top pharmaceutical companies for major depressive disorder treatment @ Major Depressive Disorder Clinical Trials
Table of Contents
1
Major Depressive Disorder Market Key Insights
2
Major Depressive Disorder Market Report Introduction
3
Executive Summary of Major Depressive Disorder (MDD)
4
Key Events
5
Epidemiology and Market Methodology of Major Depressive Disorder (MDD)
6
Major Depressive Disorder (MDD) Market Overview at a Glance
6.1
Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2
Market Share of Major Depressive Disorder (MDD) By Therapies (%) in the 7MM in 2026
6.3
Market Share of Major Depressive Disorder (MDD) By Therapies (%) in the 7MM in 2036
7
Disease Background And Overview of Major Depressive Disorder (MDD)
7.1
Introduction
7.2
Causes
7.3
Signs And Symptoms
7.4
Diagnosis
7.5
Treatment and Management
8
Epidemiology and Patient Population of Major Depressive Disorder (MDD)
8.1
Key Findings
8.2
Assumption and Rationale
8.3
Total Diagnosed Prevalent Cases of Major Depressive Disorder (MDD) in the 7MM
8.4
The United States
8.4.1
Total Diagnosed Prevalent Cases of Major Depressive Disorder (MDD) in the United States
8.4.2
Gender-specific Diagnosed Prevalent Cases of Major Depressive Disorder (MDD) in the United States
8.4.3
Severity-specific Diagnosed Prevalent Cases of Major Depressive Disorder (MDD) in the United States
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey of Major Depressive Disorder (MDD)
10
Marketed Therapies of Major Depressive Disorder (MDD)
10.1
Marketed Competitive Landscape of Major Depressive Disorder (MDD)
10.2
Lumateperone (CAPLYTA): Johnson & Johnson
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Summary of Pivotal Trials
10.2.5
Analyst Views
10.3
Esketamine (SPRAVATO): Johnson & Johnson
11
Emerging Therapies of Major Depressive Disorder (MDD)
11.1
Emerging Competitive Landscape of Major Depressive Disorder (MDD)
11.2
Seltorexant: Johnson & Johnson
11.2.1
Product Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trial Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
Azetukalner: Xenon Pharmaceuticals
12
Major Depressive Disorder Market: Seven Major Market Analysis
12.1
Key Findings
12.2
Market Outlook of Major Depressive Disorder (MDD)
12.3
Conjoint Analysis of Major Depressive Disorder (MDD)
12.4
Key Market Forecast Assumptions
12.5
Total Market Size of Major Depressive Disorder (MDD) in the 7MM
12.6
The United States Major Depressive Disorder Market
12.6.1
Total Market Size of Major Depressive Disorder (MDD) in the United States
12.6.2
Market Size of Major Depressive Disorder (MDD) by Therapies in the United States
12.7
EU4 and the UK Major Depressive Disorder Market
12.8
Japan Major Depressive Disorder Market
13
Unmet Needs of Major Depressive Disorder (MDD)
14
SWOT Analysis of Major Depressive Disorder (MDD)
15
KOL Views of Major Depressive Disorder (MDD)
15.1
Expert/KOL Interview Highlights
16
Market Access and Reimbursement of Major Depressive Disorder (MDD)
16.1
The US
16.2
In EU4 and the UK
16.3
Japan
16.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
16.5
Market Access and Reimbursement of Major Depressive Disorder (MDD) Therapies
17
Bibliography
18
Major Depressive Disorder Market Report Methodology
Related Reports
Major Depressive Disorder Clinical Trial Analysis
Major Depressive Disorder Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key MDD companies, including GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
Treatment-resistant Depression Market
Treatment-resistant Depression Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TRD companies, including Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
Bipolar Depression Market
Bipolar Depression Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bipolar depression companies, including Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, Vanda Pharmaceuticals, and others.
Postpartum Depression Market
Postpartum Depression Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key postpartum depression companies, including Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP